Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05402384 · ClinicalTrials.gov registry record · Phase 2
AVTX-801 D-galactose Supplementation in SLC35A2-CDG
A Phase 2 study, sponsored by Eva Morava-Kozicz.
- Not yet
- Registry status
- Phase 2
- Development phase
- 10
- Enrollment target
NCT05402384 is a Phase 2 study that has not yet begun recruiting, run by Eva Morava-Kozicz. The registered enrollment target is 10 participants.
The verdict
NCT05402384, a Phase 2 study, has not yet begun recruiting, sponsored by Eva Morava-Kozicz.
- NOT YET RECRUITING
- Registry status
- Phase 2
- Development phase
- 10 participants
- Enrollment target
Study Summary
This is a multicenter, randomized, double-blind, placebo-controlled, cross-over study to evaluate the efficacy and safety of AVTX-801 in subjects with SLC35A2-CDG
Interventions
- DRUG Placebo
- DRUG AVTX-801
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2027-01 |
| Est. Completion | 2028-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05402384
The ClinicalTrials.gov registry entry for NCT05402384 describes a study currently listed as not yet recruiting, categorized as Phase 2. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eva Morava-Kozicz, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05402384 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05402384 about?
NCT05402384 is a clinical study titled "AVTX-801 D-galactose Supplementation in SLC35A2-CDG". This is a multicenter, randomized, double-blind, placebo-controlled, cross-over study to evaluate the efficacy and safety of AVTX-801 in subjects with SLC35A2-CDG
What is the current status of trial NCT05402384?
This trial is currently not yet recruiting. It is a Phase 2 study. The enrollment target is 10 participants. The study started on 2027-01. Estimated completion is 2028-03.
What interventions are being tested in trial NCT05402384?
The interventions under investigation include: Placebo (DRUG), AVTX-801 (DRUG).
Who is sponsoring clinical trial NCT05402384?
This trial is sponsored by Eva Morava-Kozicz, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.